Lefamulin - Nabriva Therapeutics
Alternative Names: BC-3781; BC-3781.Ac; Lefamulin-acetate; SNV-001; XENLETALatest Information Update: 28 Aug 2024
At a glance
- Originator Nabriva Therapeutics
- Developer Nabriva Therapeutics; Sinovant Sciences; Sumitomo Pharmaceuticals; Sunovion Pharmaceuticals Canada
- Class Alkenes; Anti-infectives; Anti-inflammatories; Antibacterials; Antifibrotics; Cyclopentanes; Diterpenes; Polycyclic compounds; Small molecules; Thioglycolates
- Mechanism of Action Immunomodulators; Peptidyltransferase modulators; Protein 50S ribosomal subunit modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Community-acquired pneumonia
- Phase II Skin and soft tissue infections
- Phase I/II Mycoplasma infections
- Phase I Cystic fibrosis
- No development reported Bacterial infections; Bone and joint infections; Inflammation; Nosocomial pneumonia; Osteomyelitis; Sexually transmitted infections
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Inflammation in Austria (SC)
- 04 Dec 2023 Nabriva Therapeutics terminates a phase I/II trial in Mycoplasma infections in USA at sponsor's request (NCT05111002)
- 10 Feb 2023 Nabriva Therapeutics suspends a phase I/II trial in Mycoplasma infections in USA at sponsor request (NCT05111002)